vestimИзвестия Национальной академии наук Беларуси. Серия медицинских наукProceedings of the National Academy of Sciences of Belarus, Medical series1814-60232524-2350The Republican Unitary Enterprise Publishing House "Belaruskaya Navuka"vestim-353Research ArticleКЛИНИЧЕСКАЯ И ЭКСПЕРИМЕНТАЛЬНАЯ МЕДИЦИНАCLINICAL AND EXPERIMENTAL MEDICINEКЛЕТОЧНЫЕ МЕХАНИЗМЫ АНТРАЦИКЛИНОВОЙ КАРДИОМИОПАТИИ ПРИ ДЕЙСТВИИ АНТИБИОТИКА ДОКСОРУБИЦИНАCELL MECHANISMS OF ANTRACYCLINE CARDIOMYOPATHY UNDER ANTIBIOTIC DOXORUBICIN TREATMENTАрчаковаЛ. И.ArchakovaL. I.

д-р биол. наук, гл. науч. сотрудник, профессор.

D. Sc. (Biol.), Chief researcher, Professor.

biblio@fizio.bas-net.byНоваковскаяС. А.NovakovskayaS. A.

ст. науч. сотрудник, заведующий лабораторией.

Senior researcher, Head of the Laboratory.

novakovskaya@tut.byИнститут физиологии НАН БеларусиInstitute of Physiology of the National Academy of Sciences of Belarus201701032017018389Copyright © Арчакова Л.И., Новаковская С.А., 20172017Арчакова Л.И., Новаковская С.А.Archakova L.I., Novakovskaya S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestimed.belnauka.by/jour/article/view/353

Электронно-микроскопическим методом с применением общепринятой модели острой, подострой и хронической антрациклиновой кардиомиопатии изучены морфологические основы токсического действия антрациклинового антибиотика доксорубицина на сердечную мышцу и определена динамика поражения миокарда при действии  указанного препарата. Установлена дистрофия кардиомиоцитов и деградация их сократительного и энергетического аппарата, активация процессов апоптоза в сочетании с некрозом, аутофагией гибнущих клеток и развитием обширного заместительного фиброза, приводящих к необратимой дилатации миокарда и последующей хронической сердечной недостаточности.

In this article we presented the results of electron microscopy of the laboratory rat myocardium after doxorubicin treatment. The heart damage and the development of cardiomyopathy under antracycline antibiotic doxorubicin were established. Pathogenesis and morphology of heart complications caused by this cytostatic were studied. It was established that doxorubicin induces dystrophy, necrosis, apoptosis, and autophagy in some cardiomyocytes of damage heart. Fibrosis of the connective tissue in myocardium is a cause of tissue ischemia and the development of chronic heart failure.

доксорубицинкардиомиопатиядистрофияапоптознекрозdoxorubicin treatmentcardiomyopathyelectron microscopynecrosisapoptosisReferencesЧернова, В. А. Лекарственные и диагностические средства, применяемые в онкологической практике /В. А. Чернова. – М.: Медицина, 1982. – 216 с.Chernova V. А. Lekarstvennye i diagnosticheskie sredstva, primenyaemye v onkologicheskoi praktike [Medicines and diagnostic tools used in oncological practice], Medicine, Мoscow, RU, 1982.Лушникова, Е. Л. Морфологические и молекулярно-генетические основы дилатационной кардиомиопатии /Е. Л. Лушникова, Л. М. Непомнящих, В. Д. Розенберг. – М.: Изд-во РАМН, 2004. – 191 с.Lushnikova E. L., Nepomnyashchikh L. M., Rozenberg V. D. Morfologicheskie i molekulyarno-geneticheskie osnovy dilatatsionnoi kardiomiopatii [Morphological and molecular-genetic bases of dilatation cardiomyopathy], Publ. of the Russian Academy of Medical Sciences, Мoscow, RU, 2004.Doroshow, J. H. Doxorubicin-induced cardiac toxicity / J. H. Doroshow // N. Engl. J. Med. – 1991. – Vol. 21. – P. 843–845.Doroshow J. H. “Doxorubicin-induced cardiac toxicity”, New England Journal of Medicine, 1991, vol. 21, pp. 843–845.Hanai, K. Evaluation of cardiac function by echocardiography in dogs treated with doxorubicin / K. Hanai, K. Takaba, S. Manabe // J. Toxicol. Sci. – 1996. – Vol. 21, N 1. – P. 1–10.Hanai K., Takaba K., Manabe S., Nakano M., Kohda A., Matsuo M. “Evaluation of cardiac function by echocardiography in dogs treated with doxorubicin”, Journal of Toxicological Sciences, 1996, vol. 21, no. 1, pp. 1–10.Grenier, M. A. Epidemiology of anthracycline cardiotoxicity in children and adults / M. A. Grenier, S. E. Lipshultz // Semin. Oncol. – 1998. – Vol. 25 (Suppl. 10). – P. 72–85.Grenier M. A., Lipshultz S. E. “Epidemiology of anthracycline cardiotoxicity in children, adults”, Seminars in Oncology, 1998, vol. 25, suppl. 10, pp. 72–85.Ferrans, V. J. Pathogenesis and prevention of doxorubicin cardiomyopathy / V. J. Ferrans, J. R. Clark, Jun Zhang // Tsitologiia. – 1997. – Vol. 39, N 10. – P. 928–937.Ferrans V. J., Clark J. R., Zhang Jun, Yu Z. X., Herman E. H. “Pathogenesis, prevention of doxorubicin cardiomyopathy”, Tsitologiia, 1997, vol. 39, no. 10, pp. 928–937.Lewis, W. Interaction of adriamycin in vitro with cardiac myofibril proteins / W. Lewis, J. Kleinerman, S. Puszkin // Cancer Res. – 1982. – Vol. 50. – P. 547–553.Lewis W., Kleinerman J., Puszkin S. “Interaction of adriamycin in vitro with cardiac myofibril proteins”, Cancer Research, 1982, vol. 50, pp. 547–553.Olson, R. D. Doxorubicin cardiotoxicity may be due to its metabolite, doxorubicinol / R. D. Olson, P. S. Mushlin, D. E. Breuner // Proc. Natl. Acad. Sci. USA. – 1988. – Vol. 85. – P. 3585–3589.Olson R. D., Mushlin P. S., Breuner D. E., Fleischer S., Cusack B. J., Chang B. K., Boucek R. J. “Doxorubicin cardiotoxicity may be due to its metabolite, doxorubicinol”, Proceedings of the National Academy of Sciences of the United States of America, 1988, vol. 85, pp. 3585–3589.Sacco, G. Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity / G. Sacco, R. Giampietro, E. Salvatorelli // Br. J. Pharmacol. – 2003. – Vol. 139, N 3. – P. 641–651.Sacco G., Giampietro R., Salvatorelli E., Menna P., Bertani N., Graiani G., Animati F., Goso C., Maggi C. A., Manzini S., Minotti G. “Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites, reduced toxicity by a novel anthracycline with impaired metabolite formation, reactivity”, British Journal of Pharmacology, 2003, vol. 139, no. 3, pp. 641–651.Rosenhoff, S. H. Alteration in DNA synthesis in cardiac tissues induced by adriamycin in vivo-relationship to fatal toxicity / S. H. Rosenhoff, E. Brooks, F. Bostick // Biochem. Pharmacol. – 1975. – Vol. 24. – P. 1898–1901.Rosenoff S. H., Brooks E., Bostick F., Young R. C. “Alteration in DNA synthesis in cardiac tissues induced by adriamycin in vivo-relationship to fatal toxicity”, Biochemical Pharmacology, 1975, vol. 24, pp. 1898–1901.L’Ecuyer, T. DNA damage is an early event in doxorubicin-induced cardiac myocyte death / T. L’Ecuyer, S. Sanjeev, R. Thomas // Am. J. Physiol. Heart Circ. Physiol. – 2006. – Vol. 291, N 3. – P. 1273–1280.L’Ecuyer T., Sanjeev S., Thomas R., Novak R., Das L., Campbell W., Heide R. V. “DNA damage is an early event in doxorubicin-induced cardiac myocyte death”, American journal of physiology. Heart, circulatory physiology, 2006, vol. 291, no. 3, pp. 1273–1280.Akao, M. Mitochondrial ATP-sensitive potassium channels inhibit apoptosis induced by oxidative stress in cardiac cells / M. Akao, A. Ohler, B. O’Rourke // Circ. Res. – 2001. – Vol. 22, N 88. – P. 1267–1275.Akao M., Ohler A., O’Rourke B., Marbán E. “Mitochondrial ATP-sensitive potassium channels inhibit apoptosis induced by oxidative stress in cardiac cells”, Circulation Research, 2001, vol. 22, no. 88 (12), pp. 1267–1275.Akao, M. Differential actions of cardioprotective agents on the mitochondrial death pathway / M. Akao, B. O’Rourke, H. Kusuoka // Circ. Res. – 2003. – Vol. 7, N 92. – P. 195–202.Akao M., O’Rourke B., Kusuoka H., Teshima Ya., Jones S. P., Marbán E. “Differential actions of cardioprotective agents on the mitochondrial death pathway”, Circulation Research, 2003, vol. 7, no. 92 (2), pp. 195–202.Xu, X. Мolecular pharmacology of the interaction of anthracyclines with iron / X. Xu, H. L. Persson, D. R. Richardson // Mol. Pharmacol. – 2005. – Vol. 68, N 2. – P. 261–271.Xu X., Persson H. L., Richardson D. R. “Мolecular pharmacology of the interaction of anthracyclines with iron”, Molecular Pharmacology, 2005, vol. 68, no. 2, pp. 261–271.Shi, J. Apoptosis in Anthracycline Cardiomyopathy / J. Shi, E. Abdelwahid, L. Wei // Curr. Pediatr. Rev. – 2011. – Vol. 7, N 4. – P. 329–336.Shi J., Abdelwahid E., Wei L. “Apoptosis in Anthracycline Cardiomyopathy”, Current Pediatric Reviews, 2011, vol. 7, no. 4, pp. 329–336.Boucek, R. J. J. Persistant effects of doxorubicin on cardiac gene expression / R. J. J. Boucek, A. Miracle, M. Anderson // J. Mol. Cell Cardiol. – 1999. – Vol. 31. – P. 1435–1446.Boucek R. J. J., Miracle A., Anderson M., Engelman R., Atkinson J., Dodd D. A. “Persistant effects of doxorubicin on cardiac gene expression”, Journal of Molecular, Cellular Cardiology, 1999, vol. 31, pp. 1435–1446.Yin, X. Induction of antioxidants by adriamycin in mouse heart / X. Yin, H. Wu, Y. Chen // Biochem. Pharmacol. – 1998. – Vol. 56, suppl. 1. – P. 87–93.Yin X., Wu H., Chen Y., Kang Y. J. “Induction of antioxidants by adriamycin in mouse heart”, Biochemical Pharmacology, 1998, vol. 56, suppl. 1, pp. 87–93.Creutzig, U. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML / U. Creutzig, S. Diekamp, M. Zimmermann // Pediatr. Blood Cancer. – 2007. – Vol. 48. – P. 651–662.Creutzig U., Diekamp S., Zimmermann M., Reinhardt D. “Longitudinal evaluation of early, late anthracycline cardiotoxicity in children with AML”, Pediatric Blood, Cancer, 2007, vol. 48, pp. 651–662.Розенберг, В. Д. Дилатационная кардиомиопатия: Общая патология и патоморфология / В. Д. Розенберг, Л. М. Непомнящих. – М.: Изд-во РАМН, 2004. – 352 с.Rosenberg V. D., Nepomnyashchikh L. M. Dilatatsionnaya kardiomiopatiya: Obshchaya patologiya i patomorfologiya [Dilation cardiomyopathy: general pathology and pathomorphology], Publ. of the Russian Academy of Medical Sciences, Мoscow, RU, 2004.Технический кодекс установившейся практики. ТКП 125-2008 (02040). Надлежащая лабораторная практика: постановление Министерства здравоохранения Респ. Беларусь, 28 марта 2008 г., № 56.Health Ministry of the Republic of Belarus, TKP 125-2008 (02040): Nadlezhashchaya Laboratornaya Praktika [TKP 125-2008 (02040): Good Laboratory Practice], BY, 2008.European Convention for the Protection of Vertebrate Animals Used for Experimentation and other Scientific Purposes, N 123 of 18 March 1986; Protocol of Amendment to the European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes, Strasbourg, 22 June 1998.European Convention for the Protection of Vertebrate Animals Used for Experimentation and other Scientific Purposes, N 123 of 18 March 1986; Protocol of Amendment to the European Convention for the Protection of Vertebrate Animals used for Experimental, other Scientific Purposes, Strasbourg, 22 June 1998.Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin / S. Zhou [et al.] // Cancer Res. – 2001. – Vol. 61. – P. 771–777.Zhou S., Starkov A., Froberg M. K., Leino L. R., Wallace B. K. “Cumulative, irreversible cardiac mitochondrial dysfunction induced by doxorubicin”, Cancer Research, 2001, vol. 61, pp. 771–777.Боголепов, Н. Н. Методы электронно-микроскопического исследования мозга / Н. Н. Боголепов. – М., 1976. – 71 с.Bogolepov N. Metody elektronno-mikroskopicheskogo issledovaniya mozga [Methods of electron microscopic study of brain], Moscow, RU, 1976.

The authors declare that there are no conflicts of interest present.